Published in J Virol on March 10, 2010
HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog (2011) 2.68
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Revisiting HIV-1 uncoating. Retrovirology (2010) 1.27
Superresolution imaging of HIV in infected cells with FlAsH-PALM. Proc Natl Acad Sci U S A (2012) 1.13
HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol (2015) 1.11
Solution conformations of prototype foamy virus integrase and its stable synaptic complex with U5 viral DNA. Structure (2012) 1.07
Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology (2012) 1.04
Mutations affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA nuclear import. Retrovirology (2011) 1.01
A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly. J Virol (2013) 0.99
Structural properties of HIV integrase. Lens epithelium-derived growth factor oligomers. J Biol Chem (2010) 0.98
Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem (2011) 0.95
Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative mutant S6. J Virol (2010) 0.87
Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. J Virol (2015) 0.85
Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development. Front Microbiol (2011) 0.85
Knockdown of the cellular protein LRPPRC attenuates HIV-1 infection. PLoS One (2012) 0.83
Structural and functional role of INI1 and LEDGF in the HIV-1 preintegration complex. PLoS One (2013) 0.82
A perspective of the dynamic structure of the nucleus explored at the single-molecule level. Chromosome Res (2011) 0.81
Multifunctional facets of retrovirus integrase. World J Biol Chem (2015) 0.78
Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication. J Virol (2015) 0.78
The N-end rule and retroviral infection: no effect on integrase. Virol J (2013) 0.77
Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) to Facilitate the IN Assembly and Non-enzymatic Function Through the IN Precursor Form with Reverse Transcriptase. J Virol (2016) 0.77
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Cellular minichromosome maintenance complex component 5 (MCM5) is incorporated into HIV-1 virions and modulates viral replication in the newly infected cells. Virology (2016) 0.75
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet (1998) 9.84
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Structural organization of authentic, mature HIV-1 virions and cores. EMBO J (2003) 4.32
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell (2007) 4.25
Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog (2009) 4.24
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
X-ray structures of the hexameric building block of the HIV capsid. Cell (2009) 4.08
Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol (2001) 3.66
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A (2006) 3.43
Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J Virol (2000) 2.80
Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog (2007) 2.75
Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol (2003) 2.73
Association of Nef with the human immunodeficiency virus type 1 core. J Virol (1999) 2.62
Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol (2006) 2.57
The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology (2007) 2.54
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol (2005) 2.54
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A (1997) 2.52
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.51
Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol (2005) 2.47
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol (2006) 2.31
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci U S A (2002) 2.19
The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol (2006) 2.17
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
The road to chromatin - nuclear entry of retroviruses. Nat Rev Microbiol (2007) 2.13
Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol (2005) 1.79
Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology (2000) 1.77
Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag). J Virol (2000) 1.76
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol (1996) 1.71
Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol (2001) 1.65
Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol (2004) 1.58
Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol (2003) 1.55
Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol (2009) 1.53
Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol (2006) 1.48
Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology (2006) 1.38
Uncoating of HIV-1 requires cellular activation. Virology (2005) 1.36
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem (2006) 1.32
Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J Virol (2009) 1.32
Extensive regions of pol are required for efficient human immunodeficiency virus polyprotein processing and particle maturation. Virology (1996) 1.26
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J Virol (2005) 1.24
Characterization of the nuclear import pathway for HIV-1 integrase. J Biol Chem (2001) 1.20
Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets (2009) 1.13
Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virology (1999) 1.13
Viral and cellular factors that regulate HIV-1 uncoating. Curr Opin HIV AIDS (2006) 1.11
Host factors involved in resistance to retroviral infection. Microbiol Immunol (2008) 1.09
Restoration of wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J Virol (2001) 1.05
VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology (2008) 1.03
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
Capsid stability and replication of human immunodeficiency virus type 1 are influenced critically by charge and size of Gag residue 183. J Gen Virol (2007) 1.02
Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. J Virol (1997) 1.01
The effect of capsid mutations on HIV-1 uncoating. Virology (2006) 0.99
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg Med Chem (2009) 0.96
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
HIV-1 capsid protein and cyclophilin a as new targets for anti-AIDS therapeutic agents. Infect Disord Drug Targets (2007) 0.81
Capsid (CA) protein as a novel drug target: recent progress in the research of HIV-1 CA inhibitors. Mini Rev Med Chem (2009) 0.80
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. J Virol (2009) 1.26
Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol (2004) 1.20
Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol (2009) 1.09
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus. PLoS One (2010) 0.99
High-throughput, sensitive quantification of repopulating hematopoietic stem cell clones. J Virol (2010) 0.95
A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites. J Virol (2006) 0.94
Subcellular localization of feline immunodeficiency virus integrase and mapping of its karyophilic determinant. J Virol (2003) 0.86
Correct integration mediated by integrase-LexA fusion proteins incorporated into HIV-1. Mol Ther (2002) 0.85
A new functional role of HIV-1 integrase during uncoating of the viral core. Immunol Res (2010) 0.83
Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. Immunol Res (2010) 0.81
Rapid size dependent deletion of foreign gene sequences inserted into attenuated HIV-1 upon infection in vivo: implications for vaccine development. Curr HIV Res (2005) 0.76
The nuclear pore complex: a new dynamic in HIV-1 replication. Nucleus (2011) 0.76
Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library. Antimicrob Agents Chemother (2011) 0.75